Royalty Report: Drugs, Cancer, Therapeutic – Collection: 63131

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Diagnostic
  • Alzheimer’s disease
  • Biotechnology
  • Diabetes Treatment
  • Proteins
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 63131

License Grant
The company entered into an exclusive license agreement with the University for sales of licensed products developed from the licensed technology.
License Property
The company is currently conducting a Phase 1 study in patients with pancreatic cancer, for a duration of approximately 24 months. The first patient was enrolled in January 2016. This study is expected to include a dose-escalation phase with 8-week cycles of treatment at each dose level. At least two cycles of therapy at each dose level are anticipated in this trial, with continued treatment permitted for patients with clinical responses or stable disease. The projected safety profile suggests that repeat cycles would be well tolerated. Additional clinical trials will be subsequently required if the results of the Phase 1 pancreatic cancer trial are positive.
Field of Use
This agreement pertains to pancreatic cancer in the drug industry.

IPSCIO Record ID: 2512

License Grant
This agreement grants the Company an exclusive world-wide license to patents, patent applications, and other intellectual property related to GCS-100 Material.
License Property
The Company's lead drug candidate GCS-100 (formerly known as GBC-590), a potential treatment for multiple forms of cancer, recently completed Phase II(a) clinical trials for pancreatic cancer and completed Phase II(a) clinical trials for colorectal cancer in 2001.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 359135

License Grant
Licensor entered into a license agreement with Chinese Licensee, thereby granting to Licensee exclusive rights to commercialize Licensor's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.
License Property
Pritumumab, a drug candidate using monoclonal antibodies for the treatment of various cancer types. Pritumumab may offer an advantage over existing treatments. Pritumumab works by binding to a target on the surface of cancer cells called ectodomain vimentin (also referred to as cell-surface vimentin). The target, generally referred to as an antigen, is prevalent in many different tumor types and is not being targeted by any other biopharmaceutical companies. By binding to this target, Pritumumab is able to make the tumor cells “known” to the body’s immune system, resulting in potentially several types of immune responses, including anti-idiotype, apoptosis, antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to death of the cancer cells and overall depletion of the tumor.
Field of Use
Field of use is for the treatment of brain cancer and pancreatic cancer and exploring in its use against viruses.

IPSCIO Record ID: 1334

License Grant
The Licensor signed an Agreement with the Licensee granting  exclusive worldwide rights to develop and commercialize KB001-A for all indications.
License Property
Under this Agreement, the Licensee is solely responsible for the research, development, manufacture, and commercialization of KB001-A, except that the Licensor retained responsibility for developing and commercializing the product for CF and bronchiectasis.

The Licensee is solely responsible for the costs and development of KB001-A for pneumonia prevention and other hospital indications. We are currently planning a Phase 2 trial in CF.

Field of Use
KB001-A, a Humaneeredâ„¢, anti-PcrV PEGylated Fab form of antibody that is being developed for the prevention and treatment of Pa infections in mechanically ventilated patients and chronically infected CF patients.

IPSCIO Record ID: 125020

License Grant
University granted the Company a royalty bearing, exclusive worldwide license, limited to the field of Alzheimer’s Immunotherapy and Diagnostics.
License Property
United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use”, filed April 7, 2009 and granted May 29, 2012.
Field of Use
This agreement pertains to the drug industry relating to Alzheimer's Immunotherapy and Diagnostics.

IPSCIO Record ID: 27942

License Grant
The Company announced that it had begun to develop its lung cancer-specific drug compound L-DOS47.

For this purpose, the Company entered into a worldwide exclusive license with the Licensor, through which it obtained the right to combine an antibody that specifically binds to lung adenocarcinoma cells with minimal cross reactivity to other tissues with Company's DOS47â„¢ technology.

License Property
A patent application in respect of the antibody has been filed in Canada, the United States, and as a PCT filing. L-DOS47 is still in the pre-clinical stage though the Company intends to seek approval from the FDA for a Phase I clinical study in lung adenocarcinoma patients.
Field of Use
The rights granted relate to biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the treatment and prevention of cancer based on its proprietary technologies.

IPSCIO Record ID: 238987

License Grant
The Parties entered into an exclusive commercial sub-license agreement, relating to the development and marketing of KRX-0403. The KRX-0403 license agreement provides for worldwide sublicense rights, with the exception of the Far East. Under the agreement, Licensee has assumed responsibility for the development and marketing of KRX-0403.

The Canadian Licensor grants to Licensee an exclusive sublicense, even as against the Licensor, under the Patent Rights to develop and have developed, market and have marketed, sell and have sold, distribute and have distributed, and manufacture and have manufactured, the Licensed Products in the Territory, said license to include the right to further sub-license.

License Property
Licensor is engaged in research and development related to the drug known as AVLB, including all of its forms.

Licensed Product shall mean anhydrovinblastine sulfate (AVLB), with the chemical name 3 ,4 – dehydrovinblastine sulphate and molecular formula C4Jls~40s-H2SO4•.

KRX-0403 is a novel spindle poison in the vinca alkaloid class of drugs. Derived from the periwinkle plant, the family of vinca alkaloids and the mechanistically similar family of taxanes include some of the most successful cancer drugs ever developed, including Navelbine®, Taxol® and Taxotere®. Although these agents have been widely prescribed, they can be very toxic and may cause varying degrees of neurotoxicity and/or bone marrow suppression. We believe that an equally or more effective but less toxic therapy would satisfy a substantial need for these patients. In a number of pre-clinical animal studies of human cancers, including non-small cell lung cancer, KRX-0403 demonstrated greater anti-cancer activity and lower toxicity than currently marketed vinca alkaloids. In a Phase I clinical trial designed to evaluate the safety, toxicity profile and pharmacokinetics of KRX-0403 in patients with different tumor types, including lung cancer, breast cancer, sarcoma and colon cancer, KRX-0403 was demonstrated to be safe in humans with reversible and manageable toxicities. We believe KRX-0403 may have utility in the treatment of breast, lung and other forms of cancer. We plan to conduct additional dosing clinical trials for KRX-0403.

Field of Use
The Licensee is a biopharmaceutical focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

IPSCIO Record ID: 93480

License Grant
The Third Addendum and the Clarification Agreement provide the company with an exclusive world-wide license, with a right to sublicense, to use the Cell-in-a-Box® technology for the development of treatments for cancer and use of the Cell-in-a-Box® trademark and its associated technology using genetically modified HEK293 cells overexpressing the cytochrome P450 2B1 gene that are encapsulated using the licensed technology.
License Property
The Technology utilizes a cellulose-based live cell encapsulation technology, referred to  as “Cell in-a-Box®,” to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes.

The Cell-in-a-Box® technology, is a means to protect, isolate, store and transport living cells.
Bac-in-a-Box involves the technology which allows living cells to be encapsulated into bio-inert polymer beads. This technology allows both living eukaryotic (e.g. stem cells) and bacterial cells (e.g. probiotics) to be encapsulated in order to protect, store, isolate and transport them.

Field of Use
This agreement pertains to the medical drug industry relating to treatments for cancer.

IPSCIO Record ID: 260

License Grant
The German Licensor will grant Coronado an exclusive license to use the Pre-Clinical Know-How and under the Patent Rights to develop, use, have made by OvaMed, and commercialize and sell Product in the Coronado Territory and, subject to this Agreement, will disclose to Coronado all Pre-Clinical Know-How as soon as such Pre-Clinical Know-How becomes available.
License Property
The Licensor, a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced a binding Terms of Agreement with the Licensor, to collaborate in the development of CNDO-201, or Trichuris suis ova (TSO), for Crohn’s disease.

Under the Terms of Agreement, Licensee and Licensor have agreed to enter into a Collaboration Agreement under which the Licensor will grant the Licensee exclusive rights and Licenses under certain Licensor patent rights, pre-clinical data and clinical data from clinical trials of TSO in Crohn’s disease, including an ongoing Phase II clinical trial, for use in North America, South America and Japan.

The German Licensor will grant the Licensee exclusive rights and Licenses to Company data from planned clinical trials of TSO in Crohn’s disease for use in Europe.

Field of Use
The Licensee and the Licensor have each Licensed TSO, a novel, orally administered, natural immunomodulator that regulates T-Cells and inflammatory cytokines, from OvaMed, the manufacturer of the product, in their respective territories.

A Steering Committee comprised of the Licensee, Licensor and OvaMed representatives will oversee the development program, under which Coronado each be responsible for clinical testing on approximately 50% of the total number of patients required for regulatory approval of TSO for Crohn’s disease in the United States and Europe.

IPSCIO Record ID: 299281

License Grant
University grants a worldwide, exclusive license under the Patent Rights to make and have made, to use and have used, and to offer to sell, sell or import, and have offered to sell, sold or imported, the Licensed Products in the Field of Use, and to practice and have practiced the Licensed Processes and Know-How.

University also grants the right to enter into sublicensing agreements under the Patent Rights.

License Property
The University rights are for the Method for Synthesizing Epothilones and Epothilone Analogs and any other U.S. application owned by the University that has Valid Claims covering the manufacture, use, or sale of [trans-9,10-dehydro-epothilon,D].

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.

KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.

Field of Use
The Licensee is developing its epothilone, KOS-1584, in Phase 1 clinical trials and it has shown activity in patients with non-small cell lung, ovarian, breast, pancreatic, prostate and other cancers.

IPSCIO Record ID: 28080

License Grant
Licensee holds exclusive rights to a number of patents that have issued in the U.S. and the EU covering methods for the manufacture of our ANX-201 product candidate and of various analogs and derivatives thereof, and the use of ANX-201 in connection with the HIV.
License Property
ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) for treatment of resistant HIV-infected patients. ANX-201 has shown activity against HIV drug-resistant clinical isolates in preclinical studies. The resistance profile of ANX-201 is unique among approved RTIs and has been shown to resensitize NRTI resistant viruses. In preclinical studies, anti-retroviral activity of ANX-201 has demonstrated synergistic activity with NRTIs suggesting potential clinical benefits of combination therapy.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 310513

License Grant
The Foundation conducted a clinical study for the Company for two phase II clinical trials to determine if a vaccine containing AE37 plus GM-CSF or another peptide vaccine compound (GP2) plus GM-CSF improved patient outcomes. Pursuant to the Forbearance Agreement, the Company and the Foundation in exchange for the Foundations deferring the Company’s overdue payments, future payments and interest, the Company agreed, among other things to pay the Foundation certain royalties and accelerated payments.
License Property
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.

In 2006 Phase I clinical trial was completed of AE37 in breast cancer, including a phase Ib safety and immunology study of AE37 in combination with GM-CSF in 16 breast cancer patients who had completed all first-line therapies and who were disease-free at the time of enrollment to the study (Holmes et al. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;263426-33).

The Foundation conducted the study, under the sponsorship of an institute affiliated with the United States Military until the IND #12229 was transferred to the Company, after which Foundation continued trial management on behalf of the Company.

The Foundation is a nonprofit organization dedicated to advancing medicine by administering, managing and supporting preeminent scientific programs.

Field of Use
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is for the treatment of breast cancer.

Licensee is an oncology company focused on the modulation of the immune system to treat cancer and is developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.